JP2017538659A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538659A5
JP2017538659A5 JP2017512982A JP2017512982A JP2017538659A5 JP 2017538659 A5 JP2017538659 A5 JP 2017538659A5 JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017538659 A5 JP2017538659 A5 JP 2017538659A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
group
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049221 external-priority patent/WO2016040505A1/en
Publication of JP2017538659A publication Critical patent/JP2017538659A/ja
Publication of JP2017538659A5 publication Critical patent/JP2017538659A5/ja
Pending legal-status Critical Current

Links

JP2017512982A 2014-09-10 2015-09-09 Ｓｍｙｄ阻害剤 Pending JP2017538659A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048773P 2014-09-10 2014-09-10
US62/048,773 2014-09-10
US201562146799P 2015-04-13 2015-04-13
US62/146,799 2015-04-13
PCT/US2015/049221 WO2016040505A1 (en) 2014-09-10 2015-09-09 Smyd inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020013314A Division JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤

Publications (2)

Publication Number Publication Date
JP2017538659A JP2017538659A (ja) 2017-12-28
JP2017538659A5 true JP2017538659A5 (enExample) 2018-10-18

Family

ID=55459528

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512982A Pending JP2017538659A (ja) 2014-09-10 2015-09-09 Ｓｍｙｄ阻害剤
JP2020013314A Pending JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤
JP2022118248A Pending JP2022163087A (ja) 2014-09-10 2022-07-25 Ｓｍｙｄ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020013314A Pending JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤
JP2022118248A Pending JP2022163087A (ja) 2014-09-10 2022-07-25 Ｓｍｙｄ阻害剤

Country Status (13)

Country Link
US (4) US10266526B2 (enExample)
EP (1) EP3193600A4 (enExample)
JP (3) JP2017538659A (enExample)
KR (2) KR102496364B1 (enExample)
CN (2) CN107072205B (enExample)
AU (1) AU2015315174B2 (enExample)
BR (1) BR112017004612A2 (enExample)
CA (1) CA2960275A1 (enExample)
EA (1) EA201790317A1 (enExample)
IL (2) IL250891A0 (enExample)
MX (2) MX2017002985A (enExample)
SG (2) SG10201901192TA (enExample)
WO (1) WO2016040505A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
PT3131582T (pt) 2014-04-15 2018-10-08 Vertex Pharma Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
JP2017526706A (ja) 2014-09-10 2017-09-14 エピザイム，インコーポレイティド イソオキサゾールカルボキサミド化合物
JP2017528460A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
WO2018030550A1 (en) 2016-08-09 2018-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds with an ror(gamma)t modulating activity
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
AU2018231120B2 (en) * 2017-03-10 2022-06-23 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
US20200138827A1 (en) * 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
AU2018288018C1 (en) 2017-06-22 2022-10-20 Curadev Pharma Limited Small molecule modulators of human STING
CA3072746A1 (en) 2017-08-14 2019-02-21 Epizyme, Inc. Methods of treating cancer by inhibiting setd2
EP3837240A4 (en) * 2018-08-14 2022-04-27 Epizyme, Inc. Substituted indoles and methods of use thereof
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
EP4010341A1 (en) * 2019-08-08 2022-06-15 Université de Strasbourg Trkb positive allosteric modulators
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
WO2021134004A1 (en) * 2019-12-27 2021-07-01 Schrodinger, Inc. Cyclic compounds and methods of using same
US20230133671A1 (en) * 2020-02-19 2023-05-04 Epizyme, Inc. Setd2 inhibitors and related methods and uses, including combination therapies
WO2021257544A1 (en) 2020-06-16 2021-12-23 Icahn School Of Medicine At Mount Sinai Sox11 inhibitors for treating mantle cell lymphoma
EP4263535A1 (en) 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
CN114246851B (zh) * 2021-11-09 2024-01-26 澳门科技大学 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途
CN114702552B (zh) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 mTORC2抑制剂
WO2023192665A2 (en) * 2022-04-01 2023-10-05 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
GB2620976B (en) * 2022-07-28 2024-07-24 Jones Paul Amido-amine hardener
CN120981228A (zh) * 2022-11-17 2025-11-18 腾维治疗公司 化合物、组合物和方法
CN120882411A (zh) * 2022-11-17 2025-10-31 腾维治疗公司 化合物、组合物和方法
WO2024158863A1 (en) * 2023-01-25 2024-08-02 The Rockefeller University Sulfonamide-1h-pyrrole-2-carboxamide inhibitors of sars-cov-2 nsp14 methyltransferase and derivatives thereof
CN116327748B (zh) * 2023-04-21 2024-09-17 武汉科技大学 联合用药物在制备抗肿瘤药物中的用途
WO2025165834A1 (en) * 2024-01-31 2025-08-07 Ensem Therapeutics, Inc. Urea derivatives of tricyclic compounds, and compositions and methods thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441195A (en) * 1993-12-30 1995-07-17 Smithkline Beecham Corporation Phenylmethyl hexanamides, and the use thereof
WO1998022432A1 (en) * 1996-11-18 1998-05-28 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
CZ20021009A3 (cs) * 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
CA2415961A1 (en) 2000-07-19 2002-01-24 Hirohiko Nishiyama Production method of 1-substituted-1,2,3-triazole derivatives
AUPR034000A0 (en) * 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AU2002338334B8 (en) * 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JP2004175739A (ja) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd 医薬組成物
JP2004315395A (ja) * 2003-04-14 2004-11-11 Yamanouchi Pharmaceut Co Ltd 新規な安息香酸誘導体又はその塩
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
CA2538759C (en) * 2003-09-12 2015-11-03 Elixir Pharmaceuticals, Inc. Substituted heterocyclic compounds as sirtuin inhitibitors
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
EP1718611A4 (en) * 2004-02-13 2009-09-23 Harvard College 3-3-DI-SUBSTITUTED OXINDOLES AS INHIBITORS OF INITIATION OF TRANSLATION
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
CA2588607A1 (en) * 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
US20090253671A1 (en) * 2005-03-04 2009-10-08 Astrazeneca Ab Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
AU2006232620A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
WO2007002220A2 (en) * 2005-06-21 2007-01-04 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as beta-secretase inhibitors
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
PE20071092A1 (es) * 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2043634A2 (en) * 2006-07-12 2009-04-08 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
WO2008016666A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
JP2010513263A (ja) * 2006-12-15 2010-04-30 ファイザー・プロダクツ・インク ベンズイミダゾール誘導体
CA2672373C (en) * 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PE20091576A1 (es) * 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
WO2009143039A2 (en) * 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
ES2620027T3 (es) * 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
WO2012050393A2 (ko) * 2010-10-14 2012-04-19 제이더블유중외제약 주식회사 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
CA2820035A1 (en) * 2010-12-08 2012-06-14 Lycera Corporation Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
EP2532661A1 (en) * 2011-06-10 2012-12-12 Syngenta Participations AG Novel insecticides
CN103635474B (zh) * 2011-06-17 2016-04-27 巴斯利尔药物股份公司 三环抗生素
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
CN103877078B (zh) * 2012-12-20 2017-03-15 上海交通大学医学院 Senp2小分子抑制剂及其应用
JP2017526706A (ja) 2014-09-10 2017-09-14 エピザイム，インコーポレイティド イソオキサゾールカルボキサミド化合物
US20170247326A1 (en) 2014-09-10 2017-08-31 Epizyme, Inc. Substituted Pyrrolidine Carboxamide Compounds
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
JP2017528460A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
US20170253601A1 (en) 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds

Similar Documents

Publication Publication Date Title
JP2017538659A5 (enExample)
JP2020090520A5 (enExample)
JP2017528461A5 (enExample)
JP2017511801A5 (enExample)
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2017528464A5 (enExample)
US9546156B2 (en) N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
AU2017221802B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
US9790210B2 (en) N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
AU2015330506B2 (en) EGFR inhibitor, and preparation and application thereof
RU2632908C2 (ru) Гетероциклическое производное и фармацевтическое средство
US9969694B2 (en) N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
JP2017527577A5 (enExample)
JP2020503299A5 (enExample)
CN112601747B (zh) 作为malt1抑制剂的吡唑衍生物
JP2011510995A5 (enExample)
JP2017538659A (ja) Ｓｍｙｄ阻害剤
US20160280702A1 (en) Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
JP2019519595A (ja) 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
MXPA05007990A (es) Compuestos de tienopirimidina y uso de los mismos.
JP2017528460A5 (enExample)
JP2017526706A5 (enExample)
JP2017527577A (ja) 置換ピロリジン化合物